Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 16, 2024

Gradual treatment effect from mesenchymal stem cell on steroid-refractory aGVHD in patients receiving above 8 infusions and with gut involvement: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

EJErlie JiangKQKun QianLWLu Wang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jiang et al. (2024) studied this question.

synapsesocial.com/papers/68e60240b6db643587595ef6https://doi.org/10.21203/rs.3.rs-4588261/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial2024 · 27 citations
  2. 2First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation2012 · 657 citations
  3. 3Mesenchymal stem cells and immunomodulation: current status and future prospects2016 · 1,165 citations
  4. 4Acute Graft-versus-Host Disease — Biologic Process, Prevention, and Therapy2017 · 1,334 citations
  5. 5Steroid-Refractory Acute GVHD: Predictors and Outcomes2011 · 236 citations